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Introduction R, propane-2-amine], also known as 'Adam' or 'Ecstasy', is a chiral compound and a very popular drug of abuse leading to feelings of euphoria and energy and a desire to socialize (Kalant, 2001) . The S-enantiomer of MDMA is known to be more potent than the R-enantiomer in producing the distinctive subjective effects that are characteristic for ecstasy. However, it can induce severe acute toxic symptoms such as tachycardia, hypertension, hyperthermia, and hepatotoxicity and severe or even fatal intoxications have been described (Fallon et al., 1999; Kalant, 2001) .
Concerning chronic toxicity, data from animal experiments strongly suggest that these compounds can cause irreversible damage to serotoninergic nerve terminals in the central nervous system (Kalant, 2001; Monks et al., 2004; de la Torre et al., 2004; Easton and Marsden, 2006) . Decreased levels of the serotonin metabolite 5-hydroxyindoleacetic acid (McCann et al., 1994) and serotonin transporters (McCann et al., 1998) found in recreational MDMA users as compared to control subjects with no history of MDMA exposure point in the same direction. However, as the history of drug abuse of the studied MDMA users relied on self-report, it could not be excluded that these findings were (in part) attributable to concomitant abuse of other drugs of abuse (Gouzoulis-Mayfrank and Daumann, 2006) . R-and S-MDMA also differ in their dose-response curves for changes in serotonergic function and neurotoxicity and their in vivo kinetics are known to be different (Fallon et al., 1999; Kalant, 2001; Kraemer and Maurer, 2002; Peters et al., 2003; Pizarro et al., 2004; Peters et al., 2005) .
This article has not been copyedited and formatted. The final version may differ from this version. (Maurer, 1996; Maurer et al., 2000; de la Torre et al., 2004) . In urine samples of recreational MDMA users, mainly conjugated HMMA can be detected (Shima et al., 2008) .
However, it has been shown that after ingestion of racemic MDMA, the S-enantiomer is eliminated at a higher rate than the R-enantiomer (Fallon et al., 1999; Kalant, 2001; Kraemer and Maurer, 2002; Peters et al., 2003; Pizarro et al., 2004; Peters et al., 2005) . Enantioselective metabolism is the most likely explanation for the enantioselective pharmacokinetics of MDMA and was observed for the cytochrome P450 (P450)-mediated phase I metabolism and for the COMT-catalyzed methylation (Meyer et al., 2008a; Meyer and Maurer, 2009) .
Recently, human UGT enzymes involved in the glucuronidation of racemic HMMA were investigated and human UGT2B15 was identified as the only isoform with adequate enzyme activity towards the described reaction (Shoda et al., 2009 ).
However, the authors did not take into consideration that two different diastereomeric glucuronides, namely R-and S-HMMA O-glucuronides, should be formed.
Concerning all these points, the question arises whether the glucuronidation of HMMA is enantioselective too and contributes also to the pharmacokinetic difference between the respective MDMA enantiomers. Therefore, the two diastereomeric O- and to obtain enantioselective enzyme kinetic data for the relevant UGT isoforms.
Materials and Methods
Racemic HMMA·HCl was obtained from Lipomed (Bad Saeckingen, Germany) and morphine-6-β-D-glucuronide (M6G) from Sigma Aldrich (Steinheim, Germany). Single HMMA glucuronides were synthesized in the author's laboratory as described below. (Peters et al., 2002) 
Preparation of Rat Liver Microsomes
Microsomes were prepared from rat liver by differential ultra-centrifugation (De Duve, 1971 ). RLM were prepared from eight frozen (-80°C) livers of male Wistar rats (Ch.
River, Sulzfleck, Germany). Protein concentrations of the microsomes were determined according to the method of Lowry (Lowry et al., 1951) .
Enzymatic Synthesis and Extraction of the R-and S-HMMA Glucuronides
The bioassay consisted of 2.5 mM racemic HMMA·HCl, 2 mg/ml rat liver microsomes, 5 mM MgCl 2 , 5 mM saccharolactone and 100 µg/mg protein Brij58 in a total volume of 10 ml 100 mM phosphate buffer (pH 7.4). The reaction was started with the addition of 5 mM UDPGA. After 4.5 h of incubation at 37°C, the glucuronidation was terminated with 10 ml of acetonitrile and the mixture centrifuged at 10,000 g for 20 min. The supernatant containing the R-and S-HMMA Oglucuronides was diluted 1:20 with acetonitrile containing 0.1% formic acid and was transferred to SPE cartridges (Sequant ZIC-HILIC, 1 g, 6 ml) previously conditioned triply with 5 ml of water and 5 ml of acetonitrile. After pass-through of the supernatant, the cartridges were washed triply with 5 ml of acetonitrile and with 5 ml of an acetonitrile water mixture (90:10, v/v). The cartridges were eluted three times with 2.5 ml of an acetonitrile/water mixture (50:50, v/v) and the acetonitrile part of the eluate was evaporated under reduced pressure at room temperature.
Separation of R-and S-HMMA Glucuronide
This article has not been copyedited and formatted. The final version may differ from this version. acetonitrile acidified with 0.1% formic acid at a flow rate of 1 ml/min. The eluates were separated in aliquots of 50 µl and the fractions with the two glucuronides were collected. The HPLC fractions containing the single diastereomers were diluted 1:1 with acetonitrile and submitted to solid phase extraction using ZIC-HILIC cartridges as described above. The cartridges were eluted three times with 2.5 ml of water and the combined eluates of each glucuronide were lyophilized.
Confirmation of Configuration
The elution order of the diastereomeric glucuronides on the Chirex 3012 column was determined using 100 µl of a solution of the isolated first eluting HMMA glucuronide.
After dilution with 900 µl of water the pH was adjusted to pH 5.2 with acetic acid and the mixture was incubated at 50°C for 1.5 h with 100 µl of a mixture (100 000
Fishman units per ml) of glucuronidase (EC No. 3.2.1.31) and arylsulfatase (EC No.
3.1.6.1) from Helix Pomatia L. Afterwards 10 µl of this solution as well as 10 µl of a 10 µM solution of racemic HMMA·HCl were worked-up as described previously by (Meyer and Maurer, 2009) . Briefly, the analytes were derivatized with S-HFBPCl and analyzed by GC-MS using negative-ion chemical ionization (NICI). derivatization was compared to the retention times of derivatized R-and S-HMMA which were previously described by (Meyer and Maurer, 2009 ).
Identity and Purity Confirmation of the Isolated Glucuronides
For identity check, a small amount of each diastereomer was dissolved in water and analyzed by liquid chromatography-mass spectrometry (LC-MS) as described below. with a flow rate of 1 ml/min, respectively. The injection volume was 15 µl for analysis at 230 nm and 25 µl for analysis at 280 nm.
Microsomal Incubations
Incubation mixtures (final volume: 50 µl) consisted of 100 mM phosphate buffer (pH 7.4), 5 mM MgCl 2 , alamethicin (50 µg/mg protein), 0.25 to 1 mg/ml UGT-containing microsomes and substrate at 37°C. The substrate was added after dilution of a 50 mM aqueous stock solution in the above-mentioned phosphate buffer. Reactions were started by addition of 5 mM UDPGA and terminated with 50 µl of acetonitrile.
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Initial Screening Studies
Incubations were performed with 500 µM R,S-HMMA and 1 mg/ml UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15 and UGT2B17 for 30 min. Further composition of the incubation mixtures is described under microsomal incubations.
Kinetic Studies
The kinetic constants of HMMA O-glucuronidation were derived from incubations with an incubation time of 25 min (recombinant UGTs) and 15 min (HLM). The protein concentrations were 0.25 mg/ml for UGT2B15, 0.5 for UGT1A9, UGT2B7, and UGT2B15, and 1 mg/ml for HLM. These concentrations were within the linear range of the glucuronide formation.
Enzyme kinetic constants were estimated by non-linear curve-fitting using GraphPad 
The best kinetic model was selected, considering the randomness of the residuals, the standard errors of the estimates and the correlation coefficients. Additionally, Eadie-Hofstee plots were used to check for allosteric kinetics. 
Sample preparation for microsomal incubations
After termination of the incubation, 10 µl of the internal standard (M6G, 5 µM) were added to each incubation mixture, the samples were vortexed, centrifuged (10,000 g, 10 min), 100 µl of the supernatants transferred to autosampler vials, and 10 µl-aliquots injected into the LC-MS system.
LC-MS Conditions
The analytes were separated using an Accela LC system (Thermo Fisher Scientific, TF, Dreieich, Germany) consisting of a degasser, a quaternary pump and an 
Results

Enzymatic Synthesis of R-and S-HMMA Glucuronides
Initial experiments showed that RLM were the most efficient microsomal source for enzymatic synthesis of R-and S-HMMA O-glucuronides (data not shown). Optimal incubation conditions were evaluated (data not shown) and shown to be best for: 5 mM MgCl 2 , 5 mM saccharolactone, 100 µg/mg protein Brij58, 2 mg/ml microsomal protein, 5 mM UDPGA, 2.5 mM racemic HMMA and an incubation time of 4.5 h.
Under these conditions HMMA was completely converted to the respective 
LC-MS for Diastereoselective Quantification
The applied LC-MS conditions for quantification provided separation of HMMA, M6G, 
R-and
Initial activity screening
As shown in Fig. 4 , O-glucuronidation of racemic HMMA was catalyzed by UGT1A1, UGT1A3, UGT1A8, UGT1A9, UGT2B4, UGT2B7, UGT2B15, and UGT2B17.
Kinetic Studies
Twelve HMMA concentrations ranging from 0.01 to 20 mM were used in the kinetic analysis of UGTs and HLM. The K m , V max , V max /K m values and the Hill coefficients n are listed in Table 1 . The data for UGT2B15, UGT2B17 and HLM followed the As shown in Fig. 7 , HMMA glucuronidation in the range of 1-10 µM by UGT2B7, UGT2B17 and HLM was not considerably enantioselective, but there was a slight preference for the S-diastereomer. No preference could be observed for UGT2B15
and only UGT1A9 revealed a relevant selectivity for glucuronidation of S-HMMA.
Discussion
Reference standards of the HMMA glucuronides needed for enzyme kinetic studies
were not commercially available. Therefore, the two diastereomers of HMMA Oglucuronide were synthesized enzymatically by RLM. Such bioassays for glucuronide synthesis are a versatile alternative to classical chemical synthesis, especially for mg quantities and have been used previously for a wide range of substrates (Soars et al., 2002; Uutela et al., 2009) . HMMA O-glucuronide was previously synthesized by chemical synthesis by Shima et al. (Shima et al., 2007) and by enzymatic synthesis as well (Shoda et al., 2009 ), but the two diastereomers were not isolated separately.
The final yield using chemical synthesis was 6%, which is somewhat low compared to the enzymatic synthesis presented by Shoda et al. (Shoda et al., 2009 ) with 71%
and to the yields in this study with 87% for the S-diastereomer and 44% for the Rdiastereomer.
The incubation conditions chosen for the initial screening of 12 human UGT isoforms were applicable for checking the general involvement of particular isoforms. The microsomes were not allowed to sit on ice for pre-incubation with alamethicin, because preliminary experiments showed no difference for this treatment as already described by Oleson and Court (Oleson and Court MH, 2008) . In contrast to Shoda (Shoda et al., 2009 ). In the study presented here, enzyme kinetic data not only for UGT2B15, but also for UGT1A9, UGT2B7 and UGT2B17 were recorded. Because of their very low activity, kinetics of UGT1A1, UGT1A3, UGT1A8 and UGT2B4 could not be studied. Different concentrations of UDPGA (1.0-7.5 mM) were tested and 5 mM was a saturating concentration for all isoenzymes. Unfortunately, common protein concentration could not be chosen for all isoforms because the glucuronide formation by UGT1A9, UGT2B7 and UGT2B17 was too low to obtain glucuronide concentrations suitable for reliable quantification. Duration and protein content of all incubations were within the linear range of glucuronide formation (data not shown) and less than 20% of substrate was metabolized in all incubations.
The kinetic data for UGT2B15, UGT2B17 and HLM followed classical MichaelisMenten plots (Fig. 5) . In contrast, UGT1A9 and UGT2B7 revealed sigmoidal curves and the respective Eadie Hofstee plots (Fig. 6 ) indicated autoactivation kinetics (Hill coefficients are given in Table 1 ). Such autoactivation kinetics have been previously described for glucuronidation in HLM (Hutzler and Tracy, 2002) , but also for recombinant UGTs, e.g. UGT2B7 towards 4-methylumbelliferone and 1-naphthol (Uchaipichat et al., 2008) and UGT1A10 towards dopamine glucuronidation (Itaaho et al., 2009 ).
The K m values for the formation of R-and S-HMMA O-glucuronide by UGT2B15 were in a similar range as previously described for the mixture of both diastereomers (Shoda et al., 2009) . In contrast, the respective V max values were approximately five fold higher in our study which could be explained by different incubation times and different activities of the used enzymes. According to our studies, the metabolite This article has not been copyedited and formatted. The final version may differ from this version. (Kiang et al., 2005; Mazur et al., 2009) and are not expected to be reached after intake of recreational user doses of MDMA leading to plasma concentrations of MDMA in the range of 1 µM 194 µg/l) (Fallon et al., 1999; de la Torre et al., 2000; Logan and Couper, 2001; Peters et al., 2003; Pizarro et al., 2004; de la Torre et al., 2004; Peters et al., 2005) , but can reach 10 µM and higher in severe intoxications (Peters et al., 2003; Schifano, 2004) . Therefore the glucuronidation activities of all relevant recombinant UGTs and HLM were interpolated in a range of 1-10 µM substrate concentration (Fig. 7) , to consider the activities within a relevant concentration range showing metabolite formation activities comparable to previously published data for other substrates.
Comparing the V max /K m values (Table 1 ) to values described for other glucuronidations, these were in similar ranges (Court MH et al., 2002; Ohno et al., 2008; Itaaho et al., 2009; Mazur et al., 2009 ). The higher this value, the better the overall effectiveness of the respective reaction should be. This fact sounds reasonable, as the catalytic efficiency value is getting higher with increasing affinity (low K m ) and increasing velocity (high V max ).
Enantioselective metabolism is the most likely explanation for the enantioselective pharmacokinetics of MDMA. Enantioselectivity was observed for N-demethylation and demethylenation by cytochrome P450 2C19 (CYP2C19), demethylenation by CYP2D6 (Meyer et al., 2008b) and for the COMT-catalyzed methylation of DHMA to HMMA, with a preference for the S-enantiomers (Meyer and Maurer, 2009 ). The study presented here is the first providing enantioselective enzyme kinetic data for MDMA phase II metabolism, the O-glucuronidation of HMMA.
In the case of glucuronidation marked enantioselectivity (V max /k m(S-HMMA) /V max /k m(R-HMMA) > 1.5 or < 0.67) was only observed for UGT1A9 towards S-HMMA and UGT2B7
towards R-HMMA. When looking at the interpolated values in the range of 1-10 µM, no considerable enantioselectivity by UGT2B7, UGT2B17 and HLM was detected, but there was a slight preference for S-HMMA. No preference could be observed for UGT2B15 and only UGT1A9 revealed a relevant selectivity for glucuronidation of S-HMMA. Interestingly the marked enantioselectivity for UGT2B7 towards R-HMMA seemed not to be relevant in the low concentration range, in which S-HMMA was glucuronidated even with a slightly higher activity than R-HMMA. With respect to the presented data, the O-glucuronidation of HMMA in vivo should not be expected to be enantioselective. Nevertheless, the S-enantiomer of MDMA was eliminated at a higher rate than its R-enantiomer (Fallon et al., 1999; Kalant, 2001; Kraemer and Maurer, 2002; Peters et al., 2003; Pizarro et al., 2004; Peters et al., 2005) .
Considering the results of the presented study, this pharmacokinetic differences can mainly be explained by enantioselective demethylenation to DHMA and methylation to HMMA (Meyer et al., 2008c; Meyer and Maurer, 2009) or additionally by possible enantioselective sulfation.
UGT2B15 was the most abundant isoform involved in the glucuronidation of HMMA and is known to be polymorphically expressed. Two distinct allelic variants due to a single nucleotide polymorphism are known, UGT2B15*1 and UGT2B15*2, whereas UGT2B15*1 is less frequent in Caucasians compared to other populations such as Asian, Hispanic, or African (0.45 to 0.64, respectively) (Guillemette, 2003 was described for the *1 allele (Court MH et al., 2002) whereas for the glucuronidation of androgens an increased activity of the *2 allele was described (Levesque et al., 2001 This article has not been copyedited and formatted. The final version may differ from this version. 
